Skip to main content
. 2013 Apr 2;8(4):e60350. doi: 10.1371/journal.pone.0060350

Table 2. General in vitro and in vivo features of chCE7agl-[(DOTA)n-decalysine]2 (n = 1, 3, 5).

chCE7agl-[(DOTA)-decalysine]2 chCE7agl-[(DOTA)3-decalysine]2 chCE7agl-[(DOTA)5-decalysine]2
Total number of DOTA 2 6 10
Specific activity Ca. 70 MBq/mg Ca. 400 MBq/mg Ca. 700 MBq/mg
pI >9.5 >9.5 7.8–8.3
Immunoreactivity 81.3% 51.0% 39.2%
Tumor-to-blood* 70.2±24.6 15.3±2.2 7.9±0.0
Tumor-to-Liver* 1.7±0.9 2.2±0.6 8.6±0.8
Liver-to-blood* 43.0±7.6 7.2±1.2 0.93±0.1
*

72 h p.i.